Last reviewed · How we verify
Thrombotic thrombocytopenic purpura
Approved treatments
- Mabthera · Roche
- CABLIVI · ABLYNX NV
- Mabthera · Roche
Monoclonal antibody targeting CD20 on B-lymphocytes, mediating cell lysis via CDC and ADCC. - Mabthera · Roche
Mabthera works by binding to the CD20 antigen on B-lymphocytes, triggering their destruction. - Calibvi · Ablynx Nv
Calibvi works by binding to von Willebrand factor, preventing it from interacting with platelets and forming blood clots.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Thrombotic thrombocytopenic purpura patent landscape — cliff calendar, originator estates, attackable patents
- Thrombotic thrombocytopenic purpura treatment landscape brief
- Thrombotic thrombocytopenic purpura treatment updates RSS
Frequently asked questions about Thrombotic thrombocytopenic purpura
What drugs treat Thrombotic thrombocytopenic purpura?
Tracked treatments include Mabthera, CABLIVI, Calibvi.
What is the treatment for Thrombotic thrombocytopenic purpura?
Standard treatment for Thrombotic thrombocytopenic purpura includes Mabthera, CABLIVI, Calibvi. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Thrombotic thrombocytopenic purpura patent cliff · Thrombotic thrombocytopenic purpura CI report
- Treatment: Mabthera · Roche
- Treatment: CABLIVI · ABLYNX NV
- Treatment: Mabthera · Roche
- Treatment: Mabthera · Roche
- Treatment: Calibvi · Ablynx Nv
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing